Skip to main content
All lobbying filings

Viatris Inc.

Viatris Inc. filed a Q2 report for Viatris Inc. on July 21, 2025.

Lobbying for Viatris Inc.

As filed: VIATRIS INC. for VIATRIS INC.

All filings by Viatris Inc. · Everything Viatris Inc. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Expenses
$590,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Pennsylvania

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages The Medication Affordability and Patent Integrity Act

IP Issues related to generic medicines Patent Settlements S 1553, The PREVAIL Act

Trade issues related to generic medicines Pharmaceutical supply chain

Policy related to corporate governance

S.2296 National Defense Authorization Act

HR 9747 Countinuing Appropriations and Extensions Act of 2025 (Title II, all provisions relating to Health Extenders)

 Bills named in this filing 7
  • S. 891
    Bipartisan Health Care Act
  • H.R. 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • S. 1302
    Increasing Transparency in Generic Drug Applications Act
  • H.R. 4132
    Prescription Information Modernization Act of 2025
  • S. 2027
    Prescription Information Modernization Act of 2025
  • S. 2296
    National Defense Authorization Act for Fiscal Year 2026
  • H.R. 9747
    Continuing Appropriations and Extensions Act, 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem